Page last updated: 2024-12-09

thioguanine anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2723601
CHEMBL ID727
CHEBI ID9555
SCHEMBL ID5898
SCHEMBL ID3701
MeSH IDM0584976

Synonyms (195)

Synonym
nsc-76504
AB01273926-01
AB01273926-02
DX4 ,
2-amino-1,9-dihydro-6h-purine-6-thione
AKOS003389499
KBIO1_000428
DIVK1C_000428
NCI60_041643
2-amino-1,7-dihydro-6h-purine-6-thione
nsc-752
x 27
6-mercapto-2-aminopurine
purine-6-thiol, 2-amino-
guanine, thio-
2-aminopurine-6-thiol
2-amino-6-purinethiol
wln: t56 bnm fym inj fus hz
thioguanine (tn) (glaxosmith)
SPECTRUM_000235
CMAP_000061
purine antimetabolite: antimetabolite: inhibits nucleic acid replication
thg ,
6-mercaptoguanine
TG ,
tioguanin
tioguanine
2-amino-1,9-dihydropurine-6-thione
6h-purine-6-thione, 2-amino-1,7-dihydro-
wellcome u3b
nsc752
lanvis
2-amino-6-mercaptopurine
2-aminopurine-6(1h)-thione
purine-6(1h)-thione, 2-amino-
2-amino-9h-purine-6-thiol
2-amino 6mp
tabloid
6-thioguanine
bw 5071
2-aminopurin-6-thiol
BSPBIO_001994
IDI1_000428
SMP2_000326
2-aminopurin-6-thiol [czech]
tioguanina [inn-spanish]
2-amino-6-merkaptopurin [czech]
2-amino-6-mp
einecs 205-827-2
nsc 752
hsdb 2504
tioguaninum [inn-latin]
ccris 8997
2-amino-1,7-dihydro-6h-purin-6-thion [czech]
2-thioguanine
guanine, thio- (van)
ai3-26078
thioguanine
154-42-7
C07648
6-thioguanine, hybri-max(tm), 50 x, gamma-irradiated, lyophilized powder, bioxtra, suitable for hybridoma
6-thioguanine, >=98%
thioguanine anhydrous
2-amino-6-merkaptopurin
thioguanine, anhydrous
DB00352
SPECTRUM5_001455
NCGC00094792-01
NCGC00094792-03
NCGC00094792-02
KBIO2_005044
KBIOGR_001452
KBIO2_007612
KBIOGR_002476
KBIO2_005851
KBIO3_001494
KBIO2_003283
KBIO2_002476
KBIO2_000715
KBIO3_002954
KBIOSS_000715
KBIOSS_002483
SPBIO_000849
NINDS_000428
SPECTRUM2_000695
SPECTRUM4_000926
SPECTRUM3_000577
NCIOPEN2_004153
SPECTRUM1500573
6-tg
MLS001333132
smr000857244
MLS001333131
HMS2092M11
2-amino-1,7-dihydro-purine-6-thione
2-amino-1h-purine-6(9h)-thione
bdbm50200099
2-amino-1,9-dihydro-purine-6-thione
thioquanine
2-amino-1h-purine-6(7h)-thione
chebi:9555 ,
CHEMBL727 ,
tioguanine hemihydrate
D08603
lanvis (tn)
tioguanine (inn)
HMS501F10
T0212
HMS1921E09
A809532
NCGC00188976-02
NCGC00188976-01
NCGC00094792-05
BCPE000001
154-42-7|6-thioguanine
tioguanina
2-amino-1,7-dihydro-6h-purin-6-thion
tioguaninum
wix31zpx66 ,
6-tioguanine
tioguanine [inn]
thioguanine [usan:usp]
unii-wix31zpx66
tox21_113184
tox21_300275
NCGC00254082-01
tox21_202401
NCGC00259950-01
BCP9000197
nsc757348
nsc-757348
pharmakon1600-01500573
dtxcid803652
tox21_111035
cas-154-42-7
dtxsid6023652 ,
HMS2235F05
CCG-39890
FT-0611217
NCGC00094792-06
PS-5007
thioguanine [hsdb]
thioguanine [mi]
tioguanine [who-dd]
S1774
AKOS015901298
c5h5n5s
157646-93-0
gtpl6845
2-amino-6,7-dihydro-3h-purine-6-thione
2-amino-6-mercapto-9h-purine
CCG-213953
HY-13765
CS-1497
smr004701808
MLS006010896
SCHEMBL5898
SCHEMBL3701
tox21_111035_1
NCGC00263442-01
2-amino-6-mercapto-purin
2-amino-1,7-dihydro-6h-purine-6-thione #
W-205813
W-108030
HB1379
2-amino-3,7-dihydro-6h-purine-6-thione
AC-23020
AB00918694_06
AB00174074_06
AB01273926_03
mfcd00233553
AC-8421
SR-05000002077-5
sr-05000002077
thioguanine, united states pharmacopeia (usp) reference standard
SR-05000002077-1
6-thioguano-sine
SBI-0051533.P003
6-thioguanine;6-tg;2-amino-6-mercaptopurine;2-amino-6-purinethiol
6-tg/thioguanine
Q385347
1330266-29-9
611-67-6
thioguanine2-amino-6-purinethiol
thioguanine;6-tg; 2-amino-6-mercaptopurine; 2-amino-6-purinethiol
BCP27718
HMS3865G13
CCG-266338
NCGC00263442-05
T71841
NCGC00094792-17
NCGC00263442-02
BT166463
EN300-119530
Z2299468139

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The level of 6-thioguanine nucleotide in the patient's erythrocytes was seven times the population median value, and she had intolerable hematologic toxic effects during postremission therapy with a standard dosage of mercaptopurine (75 mg/m2 per day)."( Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Chu, YQ; Evans, WE; Horner, M; Kalwinsky, D; Roberts, WM, 1991
)
0.28
" Although these derivatives did not display selective toxicity toward the hypoxic cells, they were significantly more toxic than 6-TC to this cell line at 500 microM after a 2-h exposure."( Modification of antitumor disulfide cytotoxicity by glutathione depletion in murine cells.
Kirkpatrick, DL, 1987
)
0.27
" The compounds also exhibited toxicity; however, transformation was observed at non-toxic as well as toxic doses."( Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture.
Barrett, JC; Lee, TC; Oshimura, M, 1985
)
0.27
"8-azaguanine and 6-thioguanine were both toxic to non-dividing liver cells in primary cultures."( Toxicity of 6-thioguanine and 8-azaguanine to non-dividing liver cell cultures.
Berman, JJ; Tong, C; Williams, GM, 1985
)
0.27
"Hepatotoxicity is regarded as a rare side effect of amphotericin B therapy."( Reversible hepatotoxicity related to amphotericin B.
Miller, MA, 1984
)
0.27
" A mutant cell line that lacks the ability to incorporate exogenous purines is therefore exceptionally sensitive to the toxic effects of 3-aminobenzamide."( Differential toxicity of 3-aminobenzamide to wild-type and 6-thioguanine-resistant Chinese hamster cells by interference with pathways of purine biosynthesis.
Cleaver, JE,
)
0.13
"To assay 6-MP metabolites and to correlate levels with drug compliance, disease activity, and adverse effects of treatment."( 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Cuffari, C; Latour, S; Seidman, G; Théorêt, Y, 1996
)
0.29
" However, adverse events leading to discontinuation may occur in 10-20% of patients."( 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
de Jong, DJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Jansen, JB; Mulder, CJ, 2003
)
0.32
" Primary outcome measures were the ability to tolerate 6-TG and the occurrence of adverse events."( 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
de Jong, DJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Jansen, JB; Mulder, CJ, 2003
)
0.32
" The reverse order of treatment produced a higher toxic effect than exposure to each prodrug alone."( The DNA methylation inhibitor 5-azacytidine modulates 6-thioguanine toxicity in mammalian cells.
Barbata, G; Caradonna, F; Sciandrello, G, 2003
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Despite these advantages, their therapeutic potential is limited by occasional adverse effects (myelotoxicity and hepatotoxicity) and by a relatively frequent lack of efficacy."( Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes.
Akhdar, H; Guillouzo, A; Langouet, S; Morel, F; Nicolas-Nicolaz, C; Petit, E, 2008
)
0.35
"These data indicate that the Israeli population displays a distinct TPMT genetic variability that is comprised of a mix of three major genetically diverse subpopulations, each with its unique TPMT allelic frequency distribution pattern and likelihood of developing an adverse reaction to thiopurine drugs."( Distribution of TPMT risk alleles for thiopurine [correction of thioupurine] toxicity in the Israeli population.
Adler, L; Efrati, E; Krivoy, N; Sprecher, E, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Nine patients failed thioguanine therapy: six due to adverse events, three due to therapy resistance."( Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis.
de Boer, NK; Jharap, B; Kubben, FJ; Kuik, DJ; Mulder, CJ; Russel, MG; van Asseldonk, DP; van Bodegraven, AA; Westerveld, BD, 2011
)
0.37
"Long-term use of thioguanine appears to be well tolerated and relatively safe in ulcerative colitis patients who failed conventional thiopurine therapy."( Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis.
de Boer, NK; Jharap, B; Kubben, FJ; Kuik, DJ; Mulder, CJ; Russel, MG; van Asseldonk, DP; van Bodegraven, AA; Westerveld, BD, 2011
)
0.37
"Oral thiopurines are effective and widely used in treatment of inflammatory bowel disease (IBD) in humans, although their use is limited due the development of adverse events."( Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis.
de Boer, NK; Jharap, B; Klimesova, K; Kverka, M; Lukas, M; Mulder, CJ; Rossmann, P; Tlaskalova-Hogenova, H; van Bodegraven, AA; Vos, RM, 2011
)
0.37
" The primary outcome was the occurrence of 6-thioguanine induced hepatotoxicity, scaled according to the Common Terminology Criteria for Adverse Events."( Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
de Boer, NK; Mulder, CJ; Seinen, ML; van Asseldonk, DP; van Bodegraven, AA, 2012
)
0.38
"This novel model provides clinically relevant insights into how 6TG induces SOS, and how this dangerous adverse drug reaction may be avoided by either inhibition of endothelial activation or simple changes to dosing regimens of 6TG, while still being effective treatment for colitis."( A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity.
Das, I; Duley, JA; Eri, R; Florin, TH; Jinnah, HA; Levesque, JP; Lourie, R; McGuckin, MA; McWhinney, BC; Oancea, I; Png, CW; Subramaniam, N; Winkler, IG, 2013
)
0.39
" Previous thiopurine-related adverse reactions were not encountered."( Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
Ansari, A; Duley, J; Florin, T; Oancea, I; Pavlidis, P, 2014
)
0.4
"This relatively small case series supports safe use of TG in pregnant IBD patients."( Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease.
de Boer, M; de Boer, NK; Hoentjen, F; Jansen, JM; Mahmmod, N; Mulder, CJ; Russel, MG; van Bodegraven, AA; van den Berg, SA; van der Meulen-de Jong, AE; van der Woude, CJ, 2016
)
0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" In-hospital major adverse events occurred in one patient (0."( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience.
Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018
)
0.48
"Our results provide the primary evidence that it appears to be safe and feasible to carry out the low frame rate protocol for CTO-PCI."( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience.
Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018
)
0.48
" The second approach was based on the toxic mechanism of trichloroethylene-cysteine S-conjugate sulfoxide, a Michael acceptor that undergoes rapid addition-elimination reactions with biological thiols."( Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design.
Elfarra, AA; Zhang, XY, 2018
)
0.48
" All adverse events that occurred during the follow-up were listed and graded according to the common terminology criteria (CTC)."( Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.
Bénard, MV; Buiter, HJC; de Boer, NKH; Deben, DS; Horjus, CS; Lissenberg-Witte, BI; Mulder, CJJ; Seinen, ML; Simsek, M; van Bodegraven, AA; van Luin, M; Wong, DR, 2019
)
0.51
" Forty-one per cent of patients developed adverse events: 5% were graded as severe."( Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.
Bénard, MV; Buiter, HJC; de Boer, NKH; Deben, DS; Horjus, CS; Lissenberg-Witte, BI; Mulder, CJJ; Seinen, ML; Simsek, M; van Bodegraven, AA; van Luin, M; Wong, DR, 2019
)
0.51
" Adverse events were common, but mainly mild or moderate."( Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.
Bénard, MV; Buiter, HJC; de Boer, NKH; Deben, DS; Horjus, CS; Lissenberg-Witte, BI; Mulder, CJJ; Seinen, ML; Simsek, M; van Bodegraven, AA; van Luin, M; Wong, DR, 2019
)
0.51
"To assess the incidence of hepatotoxicity in patients treated with 6TG, and to explore if a safe dose of continuous 6TG can be established."( Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
Arup, S; Frandsen, TL; Larsen, RH; Rank, CU; Schmidt, MS; Schmiegelow, K; Toksvang, LN, 2019
)
0.51
" Gastrointestinal adverse events (GI-AEs) have not yet been reported in association with CART."( Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy.
Abu-Sbeih, H; Ali, FS; Curry, JL; Foo, WC; Ge, PS; Luo, W; Neelapu, SS; Okhuysen, PC; Richards, DM; Tang, T; Wang, Y; Westin, JR, 2019
)
0.51
"Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal response."( Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
Anderson, S; Ansari, A; Bayoumy, AB; de Boer, NK; Loganayagam, A; Mulder, CJJ; Nolan, J; Sanderson, JD; Simsek, M; van Liere, ELSA; Warner, B, 2020
)
0.56
" Clinical response, adverse events, laboratory results, imaging and liver biopsies were retrospectively collected."( Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
Anderson, S; Ansari, A; Bayoumy, AB; de Boer, NK; Loganayagam, A; Mulder, CJJ; Nolan, J; Sanderson, JD; Simsek, M; van Liere, ELSA; Warner, B, 2020
)
0.56
" Thirty-seven percent (17/46) of patients experienced an adverse effect."( Low-dose thioguanine guided by therapeutic drug monitoring is a safe and effective alternative in inflammatory bowel disease patients intolerant to conventional thiopurines.
Doecke, JD; Eqbal, A; Martin, A; Patrick, D, 2023
)
0.91
"Thioguanine (TG) has been shown as a safe alternative in adults with inflammatory bowel disease (IBD) who did not tolerate conventional thiopurines [azathioprine (AZA)/mercaptopurine]."( Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.
Bayoumy, AB; Benninga, MA; de Boer, NKH; de Meij, TGJ; de Ridder, L; Hummel, T; Jagt, JZ; Mulder, CJJ; Stapelbroek, J; van Wering, HM; Wolters, VM, 2022
)
0.72
" TG-related adverse events (AE) were assessed and listed according to the common terminology criteria for AE."( Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.
Bayoumy, AB; Benninga, MA; de Boer, NKH; de Meij, TGJ; de Ridder, L; Hummel, T; Jagt, JZ; Mulder, CJJ; Stapelbroek, J; van Wering, HM; Wolters, VM, 2022
)
0.72
"In pediatric IBD, TG seems a safe alternative in case of AZA-induced pancreatitis."( Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.
Bayoumy, AB; Benninga, MA; de Boer, NKH; de Meij, TGJ; de Ridder, L; Hummel, T; Jagt, JZ; Mulder, CJJ; Stapelbroek, J; van Wering, HM; Wolters, VM, 2022
)
0.72
"Electronic databases were searched to identify studies reporting clinical responses and/or adverse events of thioguanine therapy in IBD."( Effectiveness and safety of thioguanine as a maintenance therapy of inflammatory bowel disease: Systematic review, meta-analysis and meta-regression.
Dutta, U; Jena, A; Mangipudi, UK; Neelam, PB; Sebastian, S; Sharma, V; Telaprolu, H, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The elimination half-life of TG from the peritoneal cavity was one hour."( Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion.
Cleary, SM; Horton, CN; Howell, SB; Zimm, S, 1988
)
0.27
" There was a high interpatient variation in all the pharmacokinetic parameters measured."( Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
Keen, D; Lennard, L; Lilleyman, JS, 1986
)
0.27
"4 mg/kg, 200 mg/m2, 200 microCi total) was administered to five patients; the radiolabel in the plasma declined with an initial half-life (t1/2) of 14 min and a terminal t1/2 of 19."( Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man.
Benvenuto, JA; Bodey, GP; Gottlieb, JA; Loo, TL; Lu, K; Rosenblum, MG, 1982
)
0.26
" There was a marked interindividual difference in the plasma kinetics of the two drugs; after identical doses of 100 mg/m2 an about 4-fold higher peak concentration of the parent drug was reached with 6MP."( Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb, N; Harms, DO; Janka-Schaub, G, 1998
)
0.3
" This disproportionate increase in the Css of TG suggested a capacity-limited (saturable) elimination process, and a pharmacokinetic model incorporating two compartments with capacity-limited elimination from the central compartment was developed to describe the disposition of TG."( A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
Adamson, PC; Balis, FM; Craig, CE; Kitchen, BJ; O'Brien, M; Poplack, DG, 1997
)
0.3
" The intra-individual variation was much less, suggesting that dose adjustment based on pharmacokinetic data might be useful in the future."( In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C, 1999
)
0.3
" Pharmacokinetic sampling was performed up to 6 h post dose."( 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.
Lancaster, DL; Lennard, L; Lilleyman, JS; Patel, N, 2001
)
0.31
" A wide interindividual variation in Cmax (median 313 pmol ml(-1), range 51-737) and AUC (median 586 pmol ml(-1) h, range 156-1306) was observed in the fasted state."( 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.
Lancaster, DL; Lennard, L; Lilleyman, JS; Patel, N, 2001
)
0.31
" Although there would appear to be a reduction in parent drug Cmax and AUC with food there was no difference in 6-TGN concentrations after 4 weeks of 6-TG."( 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.
Lancaster, DL; Lennard, L; Lilleyman, JS; Patel, N, 2001
)
0.31
"To examine the in vivo pharmacokinetic interaction between mesalazine and mercaptopurine."( The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Bierau, J; Bos, LP; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Stockbrügger, RW; van Gennip, A, 2005
)
0.33
" Steady-state 6-TGN concentrations were reached after 4 weeks, indicating a half-life of approximately 5 days, and measured 856 (CI95% 715-997) pmol/8 x 10 RBCs."( Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease.
Bos, LP; Bus, PJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hommes, DW; Hooymans, PM; Lohman, JJ; van Deventer, SJ, 2006
)
0.33
" Pharmacokinetic and pharmacodynamic studies of mercaptopurine and thioguanine were done in Tpmt(-/-), Tpmt(+/-), and Tpmt(+/+) mice and variables were compared among genotypes."( Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics.
Edick, MJ; Evans, WE; Grosveld, G; Hartford, C; Pui, CH; Rehg, JE; Relling, MV; Schwab, M; Vasquez, E, 2007
)
0.34
" This study investigated the pharmacokinetic profiles of mini-tablets and conventional tablets with an improved ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.56
"After giving 8 healthy beagle dogs 50 mg 6-MP in different dosage forms, plasma samples collected at different time points were analyzed for pharmacokinetic evaluation."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.56
"Two dosage forms showed the same pharmacokinetic characteristics."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.56
" A functional pharmacodynamic marker in T lymphocytes may be useful to predict therapeutic outcome of thiopurine therapy."( A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients.
Creemers, RH; Deben, DS; Drent, R; Leers, MPG; Merry, AHH; van Adrichem, AJ; van Bodegraven, AA; Wong, DR, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks."( Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978
)
0.26
"Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia."( Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine.
Bodey, GP; Freireich, EM; McCredie, KB; Whitecar, JP, 1976
)
0.26
"Three hundred twenty-six patients with acute myelocytic leukemia were randomly and prospectively assigned to four therapeutic regimens: cytosine arabinoside either alone or in combination with daunorubicin, 6-mercaptopurine, or 6-thioguanine."( Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.
Blom, J; Carey, RW; Cuttner, J; Eagan, RT; Ellison, RR; Glidewell, O; Harley, JB; Haurani, F; Holland, JH; Kyle, R; Lee, ST; Levy, RN; Moon, JH; Ribas-Mundo, M; Silver, R; Spurr, CL, 1975
)
0.25
" Dose-response curves were obtained for VCR, DNR and 6-TG in the presence and absence of isotretinoin Isotretinoin showed additive leukemic cell kills in combination with VCR and DNR."( Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients.
Hählen, K; Huismans, DR; Loonen, AH; Pieters, R; Veerman, AJ, 1991
)
0.28
" Further investigation of this drug combination in untreated patients with ANLL is warranted."( Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L, 1989
)
0.28
"A study was made of the effect of two-hour treatment of Chinese hamster cells with cytosine arabinoside (AraC) combined with hydroxyurea (HU) at the G1 phase of the cell cycle on lethal and mutagenic effects of X-radiation (50 to 400 cGy)."( [Mutations of resistance to 6-thioguanine following roentgen irradiation and subsequent treatment with cytosine arabinoside combined with hydroxyurea in Chinese hamster cells in the G1 phase].
Elisova, TV; Feoktistova, TP; Stavrakova, NM,
)
0.13
" We treated nine patients (6 with MDS, 3 with AML) with 13-cis-retinoic acid (up to 100 mg/m2/day) in combination with either 6-thioguanine (20-40 mg/day in 14-57 day courses) or with vincristine (1-2 mg as a single injection during a four-day course of RET)."( Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
Berney, JJ; Francis, GE; Guimaraes, JE; Hamblin, TJ; Knowles, SM; Mufti, GJ; Secker-Walker, LM, 1987
)
0.27
"Etoposide combined with cytarabine, doxorubicin, and 6-thioguanine was used to treat 34 patients with acute nonlymphoblastic leukemia (ANLL) in an age-adjusted protocol, with patients greater than 50 years old receiving fewer days of therapy."( Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
Anderson, NR; Arkin, CF; Bern, MM; Corkery, JC; Huberman, MS; Lokich, JJ; Paul, SD; Phillips, DF; Sonneborn, HA; Wallach, SR, 1987
)
0.27
" MDS-AML patients in this pilot study did respond better, and with minimal toxicity, when standard induction chemotherapy was given in combination with rhGM-CSF."( Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
Bernell, P; Hast, R; Kimby, E, 1994
)
0.29
" A simple procedure for the detection of TGr human peripheral blood lymphocytes was developed in our laboratory, using whole blood culturing and 5-bromodeoxyuridine (BrdU) labeling in combination with immunocytochemical staining."( Detection of 6-thioguanine-resistant human peripheral blood lymphocytes using 5-bromodeoxyuridine labeling in combination with immunocytochemical staining.
Albering, H; Hageman, G; Kleinjans, J; Stierum, R; Welle, I, 1993
)
0.29
"18 patients with acute promyelocytic leukemia (APL) were treated with HATP (Harringtonine, Adriamycin, Thioguanine, Prednisone) chemotherapy combined with chinese traditional medications."( [HATP chemotherapy combined with Chinese traditional medications in treating acute promyelocytic leukemia].
Guo, AX; Huang, SL; Wang, QE, 1993
)
0.29
" The aim of the study was quantification of 6-TG and 6-MMP, with the use of liquid chromatography combined with tandem mass spectrometry (LC/MS/MS) in solid-organ transplant recipients."( Determination of Concentrations of Azathioprine Metabolites 6-Thioguanine and 6-Methylmercaptopurine in Whole Blood With the Use of Liquid Chromatography Combined With Mass Spectrometry.
Borowiec, A; Dadlez, M; Hryniewiecka, E; Jazwiec, R; Paczek, L; Samborowska, E; Tszyrsznic, W; Zegarska, J; Zochowska, D, 2016
)
0.43
"Both tioguanine and low-dose thiopurines combined with allopurinol (LDTA) can be considered for the treatment of inflammatory bowel disease (IBD) when conventional thiopurines fail due to adverse events."( A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.
Biemans, VBC; de Boer, NKH; Dijkstra, G; Gabriëls, RY; Hoentjen, F; Pierik, MJ; Savelkoul, E; Simsek, M; West, RL, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"6-Thioguanine (6TG) is poorly absorbed after oral administration."( 6-Thioguanine: high-dose 2-H infusions in goats.
De Abreu, RA; de Vaan, GA; Schouten, TJ; Schretlen, ED; van Baal, JM; van Leeuwen, MB, 1985
)
0.27
" We found no correlation with demographic, clinical, or biochemical parameters, and differences in bioavailability might be the most important explanation to interpatient variability."( Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia.
Britt-Marie, F; Curt, P; Frost, BM; Gudmar, L; Hasle, H; Hellebostad, M; Henrik, H; Josefine, P; Jukka, K; Kanerva, J; Kjeld, S; Lönnerholm, G; Marit, H; Palle, J; Petersson, C; Schmiegelow, K, 2009
)
0.35
" We now report that long-term (five days per week for four weeks) topical daily applications of small (200 nmol) quantities of TBE-31 cause a robust systemic induction of the Keap1/Nrf2/ARE pathway and decreases the 6-TG incorporation in DNA of skin, blood, and liver of azathioprine-treated mice, indicating extraordinary bioavailability and efficacy."( Highly potent activation of Nrf2 by topical tricyclic bis(cyano enone): implications for protection against UV radiation during thiopurine therapy.
Dinkova-Kostova, AT; Honda, T; Kalra, S; Knatko, EV; Yamamoto, M; Zhang, Y, 2012
)
0.38
" The review will provide a complete insight to the readers about the mechanisms of action, efficacy to demethylate and re-express various cancer-related genes, anti-tumor activity, cytotoxicity profile, stability, and bioavailability of these drugs."( Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic.
Agrawal, K; Das, V; Hajdúch, M; Vyas, P, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Dose-restricted tioguanine (thioguanine) could expand treatment options by reducing methylated metabolites, increasing the bioavailability of 6-tioguanine nucleotides and ameliorating thiopurine intolerance or resistance."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
"The efficacy and safety of thiopurines in autoimmune hepatitis can be improved by investigational efforts that establish monitoring strategies that allow individualisation of dosage and prediction of outcome, increase bioavailability of the active metabolites and demonstrate superiority to alternative agents."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" One interpretation of the linear dose-response is that, as a result of EMS treatment, ethylation of cellular constituents occurs, which is directly responsible for the mutation."( The dose-response relationship for ethyl methanesulfonate-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells.
Brimer, PA; Gosslee, DG; Hsie, AW; Mitchell, TJ, 1975
)
0.25
" The combination treatments with 6-thioguanine and each of six agents, especially with ACNU, showed a distinct therapeutic effect against the early L-1210 leukemia at dosage levels not producing any significant antitumor activity with each agent alone (ip-ip)."( Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.
Fujimoto, S; Horikoshi, N; Hoshino, A; Inagaki, J, 1977
)
0.26
" 46% complete and 12% partial remissions were obtained in 37 patients treated with cytosine arabinoside and 6-thioguanine doubling the dosage of the above mentioned regimen followed by 3 cycles of TRAP (and COAP)."( [Induction and maintenance treatment of acute myelogenous leukemia in adults by sequential use of combination chemotherapy (author's transl)].
Fülle, HH, 1977
)
0.26
" Mutation frequency to 6TG R, an X-linked recessive phenotype, was inversely related to dosage whereas OUA R, a codominant phenotpye, occurred with equal frequency in both lines."( The relationship between induced mutation frequency and chromosome dosage in established mouse fibroblast lines.
Gartler, SM; Raskind, WH, 1978
)
0.26
" These results can account for many of the anomalies encountered in previous studies with purine analogues as selective agents, and show that some care has to be taken to characterize the mutants selected by resistance to purine analogues before meaningful dose-response relationships can be established."( Factors affecting the efficiency of purine analogues as selective agents for mutants of mammalian cells induced by ionising radiation.
Stephens, MA; Stretch, A; Thacker, J, 1976
)
0.26
" The slope of the power-time curve after drug injection relative to that obtained during unperturbed growth, was used to construct dose-response curves."( Microcalorimetric evaluation of the effects of methotrexate and 6-thioguanine on sensitive T-lymphoma cells and on a methotrexate-resistant subline.
Bäckman, P; Bermudez, J; Schön, A,
)
0.13
" The dosage of cytarabine in the intensive consolidation arm is 3 gm/M2/day IV on days 1-6."( Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
Andersen, JW; Bennett, JM; Cassileth, PA; Harrington, DP; Hines, JD; Lazarus, HM; Mazza, JJ; McGlave, PP; O'Connell, MJ; Paietta, E, 1992
)
0.28
"Fifteen patients with advanced measurable colorectal carcinoma were treated with intravenous 6-thioguanine (6-TG) at a dosage of 55 mg/m2 for 5 consecutive days every 5 weeks."( A phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma.
Pitot, HC; Rubin, J; Schutt, AJ, 1992
)
0.28
"The variant frequencies for 6-thioguanine-resistant spleen cells in different mouse strains have been estimated by autoradiography for animals without chemical treatment and in cases of in vivo mutagen dosage with ethylnitrosourea and cyclophosphamide, respectively."( Detection of 6-thioguanine-resistant spleen lymphocytes in different mouse strains by autoradiography.
Braun, R; Hüttner, E; Schöneich, J; Wielgosz, SM, 1991
)
0.28
" Dose-response curves were obtained for VCR, DNR and 6-TG in the presence and absence of isotretinoin Isotretinoin showed additive leukemic cell kills in combination with VCR and DNR."( Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients.
Hählen, K; Huismans, DR; Loonen, AH; Pieters, R; Veerman, AJ, 1991
)
0.28
" The level of 6-thioguanine nucleotide in the patient's erythrocytes was seven times the population median value, and she had intolerable hematologic toxic effects during postremission therapy with a standard dosage of mercaptopurine (75 mg/m2 per day)."( Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Chu, YQ; Evans, WE; Horner, M; Kalwinsky, D; Roberts, WM, 1991
)
0.28
" Low dosage Ara-C has been used with great success in several clinical trials."( Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells.
Hassan, HT; Rees, JK, 1989
)
0.28
" TG exhibited linear pharmacokinetics over the dosage range investigated."( Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion.
Cleary, SM; Horton, CN; Howell, SB; Zimm, S, 1988
)
0.27
" Soluble hexavalent CaCrO4, administered in either acute (5-h) or subacute (24-h) dosing regimens, induced dose-dependent cytotoxicity and mutation to 6-thioguanine resistance in Chinese hamster ovary cells but no mutation to ouabain resistance or focus formation in transformation assays, although the acute treatment induced a high frequency of conversion of 10T1/2 cells to adipocytes."( Transformation of C3H/10T1/2 mouse embryo cells to focus formation and anchorage independence by insoluble lead chromate but not soluble calcium chromate: relationship to mutagenesis and internalization of lead chromate particles.
Banh, D; Landolph, JR; Patierno, SR, 1988
)
0.27
" Compared with results obtained using 60Co gamma-rays, the ratio of the initial slope of each dose-response curve was 4-5 for cell killing, and more than 11 for mutagenesis."( Reversed dose-rate effect and RBE of 252-californium radiation in the induction of 6-thioguanine-resistant mutations in mouse L5178Y cells.
Nakamura, N; Sawada, S, 1988
)
0.27
"001) and had spent a longer time receiving reduced 6MP dosage in the 12 weeks before the study (U = 19."( Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
Keen, D; Lennard, L; Lilleyman, JS, 1986
)
0.27
" The values of these slopes were plotted against x-ray dose in rads/day to construct a dose-response relationship for 1-10 rads."( Evidence for linear response for the induction of mutations in human cells by x-ray exposures below 10 rads.
Grosovsky, AJ; Little, JB, 1985
)
0.27
" At the lower doses, the dose-response curve was linear, with no indication of a threshold."( Toxicity and mutagenicity of low dose rates of ionizing radiation from tritiated water in human lymphoblastoid cells.
Liber, HL; Little, JB; Ozaki, VH, 1985
)
0.27
" Each agent was assessed by calculating the ratio of the slopes of the dose-response plots (induced variant frequency as a function of dose of the agent used) for the two markers (DTr/TGr variants."( Comparison of the frequency of diphtheria toxin and thioguanine resistance induced by a series of carcinogens to analyze their mutational specificities in diploid human fibroblasts.
Aust, AE; Debien, K; Drinkwater, NR; Maher, VM; McCormick, JJ, 1984
)
0.27
"Between July 1, 1981 and November 1, 1982, 45 patients with acute nonlymphocytic leukemia (age, greater than or equal to 70 years) were randomly assigned to receive induction chemotherapy using either daunorubicin, cytosine arabinoside, and 6-thioguanine in full dosage (F DAT) or an attenuated schedule of the same drugs (At DAT) as part of an Eastern Cooperative Oncology Group controlled trial."( Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.
Begg, CB; Bennett, JM; Bonner, H; Glick, JH; Kahn, SB; Mazza, JJ, 1984
)
0.27
" Lengthening the duration of HF diet treatment (0, 3, 6, 16 wk) increased mammary tumor development, suggesting a time dose-response relationship."( Promotion of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis by high dietary fat in the rat: possible role of intercellular communication.
Aylsworth, CF; Jone, C; Meites, J; Trosko, JE; Welsch, CW, 1984
)
0.27
" Mutation dose-response curves for X- and UV-irradiation were established by studying lymphocytes from 11 individuals on day 10 after irradiation."( Mutations in human lymphocytes: effect of X- and UV-irradiation.
Dempsey, JL; Morley, AA; Sanderson, BJ, 1984
)
0.27
" Rechallenge with a lower dosage prompted a rapid rise in the levels, with subsequent return to normal when the medication was withdrawn."( Reversible hepatotoxicity related to amphotericin B.
Miller, MA, 1984
)
0.27
" The modified soft-agar protocol was applied using low doses (0-50 microgram/ml) of ethyl methanesulfonate and resulted in a well-defined dose-response relationship for the induction of mutants."( A modified agar assay for the quantitation of mutation at the hypoxanthine guanine phosphoribosyl transferase gene locus in Chinese hamster ovary cells.
Li, AP; Shimizu, RW, 1983
)
0.27
" The 30-fold range in thioguanine plasma levels observed in this study suggests that intermittent IV administration may provide a better means of standardizing the dosage of thioguanine."( Clinical pharmacology of oral thioguanine in acute myelogenous leukemia.
Belch, A; Birkett, L; Brox, LW, 1981
)
0.26
" When treatment with methylnitrosourea was applied at the beginning of the S phase in synchronized cells, a linear dose-response curve was obtained, whereas application of the dose after gene replication resulted in a strong reduction of the number of induced mutations."( Elimination of MNU-induced mutational lesions in V79 Chinese hamster cells.
Jenssen, D, 1982
)
0.26
" The dose-response relationship does not appear to deviate from linearity."( Determination of the expression time and the dose--response relationship for mutations at the HGPRT (hypoxanthine-guanine-phosphophoribosyl transferase) locus induced by X-irradiation in human diploid skin fibroblasts.
de Ruijter, YC; Simons, JW, 1980
)
0.26
" Although a few of the 50 mg/kg split-dose treatments were significantly higher than the comparative single-dose groups, the number of TGr lymphocytes produced by the two dosing regimens were generally similar."( The effect of time after treatment, treatment schedule and animal age on the frequency of 6-thioguanine-resistant T-lymphocytes induced in Fischer 344 rats by N-ethyl-N-nitrosourea.
Aidoo, A; Casciano, DA; George, EO; Heflich, RH; Lyn-Cook, LE, 1993
)
0.29
" In this study, we have investigated the antimutagenic effects of ascorbic acid on the frequency of 6-thioguanine-resistant (6-TGr) T-lymphocytes produced in Fischer 344 rats dosed with the direct-acting alkylating agent, N-ethyl-N-nitrosourea (ENU)."( Ascorbic acid (vitamin C) modulates the mutagenic effects produced by an alkylating agent in vivo.
Aidoo, A; Lensing, S; Lyn-Cook, LE; Wamer, W, 1994
)
0.29
"A direct semimicro conductometric method is described for the determination of five pharmaceutically-important thiol compounds, namely: N-acetylcysteine, captopril, D-penicillamine, 6-mercaptopurine and thioguanine, in bulk and in dosage forms."( Conductometric determination of some pharmaceutically important thiol compounds in dosage forms.
Belal, F; Eid, MM; Rizk, MS, 1993
)
0.29
" In individual patients, 6-TGN levels were relatively stable throughout the dosing interval ("within-dose-interval-CV" < 19%), even when sharp and high 6-MP peaks in plasma were observed."( Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment.
Bentdal, O; Bergan, S; Endresen, L; Rugstad, HE; Stokke, O, 1994
)
0.29
" Enalaprilat levels were measured and compared with 15 similar patients matched for transplant function and enalapril dosage immunosuppressed with cyclosporine and prednisone."( Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients.
Bachmann, T; Gossmann, J; Kachel, HG; Scheuermann, EH; Schoeppe, W; Thürmann, P; Weller, S, 1996
)
0.29
" The daily dosage level was 55 mg/m2 in the first 15 patients, but this was increased to 65 mg/m2 in the remaining patients due to inadequate myelosuppression at the lower dose."( Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer.
Ingle, JN; Krook, JE; Maillard, JA; Marschke, RF; Suman, VJ; Twito, DI; Windschitl, HE, 1997
)
0.3
" Maintenance dosage ranged from 120 mg twice a week to 160 mg 3 times a week."( Pulse dosing of thioguanine in recalcitrant psoriasis.
Levine, N; Silvis, NG, 1999
)
0.3
" A dosing schedule of 2 or 3 times per week is recommended to minimize the potential adverse effects."( Pulse dosing of thioguanine in recalcitrant psoriasis.
Levine, N; Silvis, NG, 1999
)
0.3
" Dose-response data of 6-MPr (s."( Combined prenatal toxicity of 6-mercaptopurine riboside and hydroxyurea in mice.
Platzek, T; Schwabe, R, 1999
)
0.3
" Daily dosing and pulse dosing were both used, from 20 mg two times a week to 120 mg daily."( Thioguanine for refractory psoriasis: a 4-year experience.
Krueger, GG; Mason, C, 2001
)
0.31
" azathioprine trial in Crohn's disease suggests oral dosing alone may obtain the same results."( Intravenous azathioprine in severe ulcerative colitis: a pilot study.
Johnson, T; Lipsky, JJ; Mahadevan, U; Mays, DC; Pike, MG; Sandborn, WJ; Tremaine, WJ, 2000
)
0.31
" Nevertheless, beside the use of RBC 6TGN determination to confirm compliance to therapy, this dosage could be useful in non-responding patients, allowing, in absence of leukopenia, to increase the dose of AZA/6-MP safely."( Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche, J; Desager, JP; Horsmans, Y; Louis, E, 2001
)
0.31
" In 22 patients with refractory Crohn's disease despite long term azathioprine therapy, their dosage was increased by 25 mg/day at eight week intervals as needed."( Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Bayless, T; Cuffari, C; Hunt, S, 2001
)
0.31
"Measurement of erythrocyte 6-TG metabolite levels is helpful in determining the adequacy of azathioprine dosage and can be used to optimise the dose of antimetabolite therapy to achieve an improved clinical response without inducing leucopenia."( Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Bayless, T; Cuffari, C; Hunt, S, 2001
)
0.31
" The study design was cross-over with each child receiving dosing in either fasted or after food over a 4 week period in each phase."( 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.
Lancaster, DL; Lennard, L; Lilleyman, JS; Patel, N, 2001
)
0.31
" A corresponding dose effect in the induction treatment of patients aged 60 years and older has been found with daunorubicin 60 vs 30 mg/m2 as part of the thioguanine/ AraC/daunorubicin (TAD) regimen with the higher dosage significantly increasing the response rate and survival in these older patients who represent a poor-risk group as a whole."( Remission induction therapy: the more intensive the better?
Andreesen, R; Aul, C; Balleisen, L; Berdel, W; Büchner, T; Eimermacher, H; Gassmann, W; Grüneisen, A; Haase, D; Haferlach, T; Hartlapp, J; Heinecke, A; Hiddemann, W; Hirschmann, WD; Löffler, H; Ludwig, WD; Maschmeyer, G; Pielken, HJ; Rasche, H; Reis, HE; Sauerland, MC; Schoch, C; Staib, P; Uhlig, J; Weh, HJ; Wörmann, B, 2001
)
0.31
" Topics reviewed include efficacy, side effects, laboratory monitoring, different dosing regimens, and proposed mechanisms of action."( 6-thioguanine in the treatment of psoriasis: a case report and literature review.
Lebwohl, MG; Sherer, DW,
)
0.13
" However, with new dosing regimens, proper laboratory monitoring, and further studies, use of 6-Thioguanine could expand in the future."( 6-thioguanine in the treatment of psoriasis: a case report and literature review.
Lebwohl, MG; Sherer, DW,
)
0.13
" AZA dosing was safely increased in patients with cirrhosis/hypersplenism."( Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report.
Emerick, KM; Emre, S; Rumbo, C; Shneider, BL, 2002
)
0.31
" A rational therapeutic strategy for thiopurine drug use is to first determine TPMT phenotype/genotype and then to adjust the dosage on an individual basis."( Analytic aspects of monitoring therapy with thiopurine medications.
Armstrong, VW; Oellerich, M; Shipkova, M; von Ahsen, N, 2004
)
0.32
" Complications of high AZA dosing make dose escalation potentially problematic."( Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis.
Emre, SH; Rumbo, C; Shneider, BL, 2004
)
0.32
" This C(i) was designed as a prognostic index by taking the area under the curve as an exact measure of the total dose-response relationship."( Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
Cornely, O; Neurohr, K; Reiser, M; Schinköthe, T; Staib, P; Staltmeier, E, 2005
)
0.33
" In analogy to the benefit of patients under the age of 60 years from high-dose AraC there are dosage related therapeutic effects in the patients over 60 years in particular for daunorubicin in the induction treatment, and for maintenance versus no maintenance in the post-remission treatment."( Treatment of older patients with AML.
Aul, C; Balleisen, L; Berdel, WE; Büchner, T; Eimermacher, H; Grüneisen, A; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Kienast, J; Lengfelder, E; Mesters, RM; Rasche, H; Reichle, A; Sauerland, MC; Schnittger, S; Schoch, C; Schumacher, A; Serve, HL; Staib, P; Wörmann, B, 2005
)
0.33
" Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease."( Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006
)
0.33
" The standard 6-TG dosage should not exceed 25 mg daily."( 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
Almer, S; de Boer, NK; Herrlinger, KR; Knoflach, P; Lukas, M; Mulder, CJ; Ochsenkühn, T; Petritsch, W; Reinisch, W; Schwab, M; Seiderer, J; Teml, A; van Bodegraven, AA; van der Merwe, SW; Vogelsang, H, 2006
)
0.33
" All errors were due to incorrect dosing or failure to administer an indicated medication."( Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
Geyer, LJ; Hawkins, DS; Taylor, JA; Winter, L, 2006
)
0.33
" Randomized trials comparing the routine strategy of AZA/6-MP dosing (based exclusively on the patient's weight) versus individualized monitoring (based on quantification of TPMP activity and/or thiopurine metabolites) are required before definitive conclusions on the most effective alternative can be drawn."( [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].
Gisbert, JP; González-Lama, Y; Maté, J, 2006
)
0.33
" We found no nodular regenerative hyperplasia in inflammatory bowel disease patients with long-term, low dosed 6-thioguanine, suggesting metabolite level-dependent effects."( Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
Bos, LP; Derijks, LJ; Driessen, A; Engels, LG; Gilissen, LP; Hooymans, PM; Stockbrügger, RW, 2007
)
0.34
" However, many physicians prescribe AZA/6MP using milligrams per kilogram (mg/kg) dosing regimens without measuring 6-TGN levels."( Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.
Lewis, JD; Miao, CL; Morales, A; Salguti, S, 2007
)
0.34
" The use of standard mg/kg dosing regimens will result in low 6-TGN levels in most patients."( Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.
Lewis, JD; Miao, CL; Morales, A; Salguti, S, 2007
)
0.34
" The addition of allopurinol enabled a reduction in mean daily prednisone dosage from 17."( Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Cao, D; Friedman, S; Hanauer, SB; Hande, SA; Sparrow, MP, 2007
)
0.34
" The mean 6-thioguanine dosage, 6-thioguaninenucleotides level, duration of use and cumulative dosage were 19."( Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
Bloemena, E; de Boer, NK; den Hartog, G; Derijks, LJ; Engels, LG; Gilissen, LP; Mulder, CJ; van Bodegraven, AA; Westerveld, BD; Zondervan, PE, 2008
)
0.35
" This fractionation effect and the curvilinearity of the early dose-response curve suggested that saturation of repair increased the yield of mutations at higher acute doses."( Studies of thioguanine-resistant lymphocytes induced by in vivo irradiation of mice.
Burkhart-Schultz, K; Jones, IM; Nelson, DO; Strout, CL, 2008
)
0.35
"We conducted a 6-month open-label dose-escalation clinical study of patients with active SLE treated with azathioprine dosed by body weight and metabolite levels."( Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.
Askanase, AD; Belmont, HM; Bernstein, L; Buyon, JP; Ishimori, M; Izmirly, PM; Seidman, E; Tseng, CE; Wallace, DJ; Weisman, MH, 2009
)
0.35
" In the main dosing study, the mean RBC 6-TGN level in patients who remained in remission during the 1-year observation time (n = 151) was 322."( Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
Abe, J; Arai, O; Hanai, H; Hosoda, Y; Iida, T; Ikeya, K; Kageoka, M; Kubota, T; Maruyama, Y; Miwa, I; Oohata, A; Takeuchi, K; Watanabe, F; Yoshirou, S, 2010
)
0.36
" We provide dosing recommendations (updates at http://www."( Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Carrillo, M; Evans, WE; Gardner, EE; Klein, TE; Pui, CH; Relling, MV; Sandborn, WJ; Schmiegelow, K; Stein, CM; Yee, SW, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Almost all gastroenterologists (97%) used weight-based dosing that was gradually escalated."( How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease?
Andersson, P; Hindorf, U, 2011
)
0.37
" The dose-response and time course of 6TG myelotoxicity were first compared in HPRT wild-type mice and HPRT-deficient transgenic mice."( Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow.
Aubrecht, J; Crooks, GM; Cuddihy, AR; Hacke, K; Kasahara, N; Lawson, GW; Lemp, NA; Rao, NP; Rozengurt, N; Schiestl, RH; Szakmary, A, 2012
)
0.38
" Optimal thiopurine dosing is challenging for preventing adverse drug reactions and improving clinical response."( Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Beaune, P; Chouchana, L; Loriot, MA; Narjoz, C; Roblin, X, 2012
)
0.38
" Adjusting dosage according to TPMT status and/or metabolite blood levels is recommended for optimising thiopurine therapy (e."( Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Beaune, P; Chouchana, L; Loriot, MA; Narjoz, C; Roblin, X, 2012
)
0.38
" This algorithm allows a dosage individualisation to optimise the management of patients under thiopurine."( Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Beaune, P; Chouchana, L; Loriot, MA; Narjoz, C; Roblin, X, 2012
)
0.38
" Median duration of 6-thioguanine therapy (median daily dosage 21 mg (9-24)) was 23 weeks (6-96)."( Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
de Boer, NK; Mulder, CJ; Seinen, ML; van Asseldonk, DP; van Bodegraven, AA, 2012
)
0.38
" 13 adverse events occurred, including 6 specific to co-therapy (3 rash, 2 abnormal liver function tests, 1 dosing error)."( Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Anderson, SH; Blaker, P; Irving, PM; Marinaki, AM; Sanderson, JD; Smith, MA, 2012
)
0.38
" Split dosing of 6TG markedly attenuated SOS but still effected immunosuppression and prevented spontaneous colitis in Winnie mice, which have a single nucleotide polymorphism mutation in Muc2."( A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity.
Das, I; Duley, JA; Eri, R; Florin, TH; Jinnah, HA; Levesque, JP; Lourie, R; McGuckin, MA; McWhinney, BC; Oancea, I; Png, CW; Subramaniam, N; Winkler, IG, 2013
)
0.39
"This novel model provides clinically relevant insights into how 6TG induces SOS, and how this dangerous adverse drug reaction may be avoided by either inhibition of endothelial activation or simple changes to dosing regimens of 6TG, while still being effective treatment for colitis."( A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity.
Das, I; Duley, JA; Eri, R; Florin, TH; Jinnah, HA; Levesque, JP; Lourie, R; McGuckin, MA; McWhinney, BC; Oancea, I; Png, CW; Subramaniam, N; Winkler, IG, 2013
)
0.39
"To investigate whether AZA therapy is optimised by individualised dosing based on thiopurine methyltransferase (TPMT) activity and 6TGN concentrations."( Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.
Bentsen, JL; Dassopoulos, T; Dubinsky, MC; Galanko, JA; Hanauer, SB; Martin, CF; Sandler, RS; Seidman, EG, 2014
)
0.4
" individualised AZA dosing in inducing and maintaining remission in adults and children with steroid-treated CD."( Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.
Bentsen, JL; Dassopoulos, T; Dubinsky, MC; Galanko, JA; Hanauer, SB; Martin, CF; Sandler, RS; Seidman, EG, 2014
)
0.4
" In this paper, we contrast 6-TG and the more widely used 6-mercaptopurine; discuss 6-TG metabolism, pharmacokinetics, dosage and schedule; and summarize many of the early studies that have shown infrequent but nevertheless positive results with 6-TG treatment of cancers."( 6-thioguanine: a drug with unrealized potential for cancer therapy.
Bertino, JR; Lubin, M; Munshi, PN, 2014
)
0.4
" TwHF extract was administered at a dosage of 10 mg three times daily for 12 months."( Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety.
Han, Y; Jiang, H; Li, T; Li, Y; Lv, W; Qiu, Z; Routy, JP; Song, X; Sun, M; Wang, F; Xie, J; Zhang, X,
)
0.13
" These compounds, 4-MP-PTOX and 4-TG-PTOX, reduce the dosage and greatly improve the therapeutic effect for microtubule damage in cancer cells."( Tubulin structure-based drug design for the development of novel 4β-sulfur-substituted podophyllum tubulin inhibitors with anti-tumor activity.
Bai, JK; Chen, T; Li, HM; Tang, YJ; Zhao, W, 2015
)
0.42
" Weight-based dosing did not improve rates of therapeutic TGN levels (under-dosed 31."( Thiopurine metabolite testing in inflammatory bowel disease.
Bell, S; Brown, S; Connell, W; Cunningham, G; Goldberg, R; Kamm, MA; Lust, M; Marsh, P; Moore, G; Schulberg, J, 2016
)
0.43
" Weight-based dosing did not increase rates of therapeutic levels but was associated with increased 6MMP shunting."( Thiopurine metabolite testing in inflammatory bowel disease.
Bell, S; Brown, S; Connell, W; Cunningham, G; Goldberg, R; Kamm, MA; Lust, M; Marsh, P; Moore, G; Schulberg, J, 2016
)
0.43
"Individualized therapy is a recent approach aiming to specify dosage regimen for each patient according to its genetic state."( Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism.
Abdelaziz, DH; Al-Ghobashy, MA; Attia, AS; El-Sayed, MH; Elhosseiny, NM; Hassan, SA; Sabry, NA, 2016
)
0.43
" The aim of the present study was to characterize the outcomes of pediatric patients with AIH and determine correlations between AZA dosing or 6-TGN metabolite levels and biochemical remission."( Outcomes in Pediatric Autoimmune Hepatitis and Significance of Azathioprine Metabolites.
Capocelli, KE; Mack, CL; McCoy, AM; Pan, Z; Sheiko, MA; Sundaram, SS, 2017
)
0.46
" Early use of adequately dosed thiopurines (≥3 months before starting ADA) was associated with improved clinical outcomes."( Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Cro
Blaker, PA; Goel, R; Irving, PM; Kariyawasam, VC; Patel, KV; Sanderson, JD; Ward, MG, 2017
)
0.46
" However, their minimum effective dose and dose-response relationship remain undefined, and evidence about their use in clinical practice is mostly heterogeneous."( A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease.
Afonso, J; Correia, L; Dias, CC; Estevinho, MM; Lago, P; Magro, F; Rosa, I; Trindade, E, 2017
)
0.46
" Dosing history, concomitant therapy, and comorbidity data were assessed."( Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine.
Barclay, ML; Mulder, CJ; Munnig-Schmidt, E; Zhang, M, 2018
)
0.48
" We aimed to compare 6-month outcomes between standard and optimized dosing strategies and define long-term predictors of thiopurine durability."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
"5 mg/kg/day (group 2) and further subgrouped depending on whether dosing was optimized to achieve 6-TGN >235 pmol/8 × 108 RBC."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
" Both dosing strategies led to similar initial 6-TGN levels (group 1 = median 209 [IQR: 155-272] with 25% of patients >235; group 2 = 196 [139-274] with 29% >235)."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
"Steroid-free clinical remission and 6-TGN levels at 6 months were no different between a standardized, fixed dosing strategy and a metabolite-driven, optimized dosing strategy."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
" Nevertheless, prospective studies of genotype-guided dosing of thiopurines are warranted to prove clinical benefit and cost-effectiveness of pretreatment NUDT15 gene testing across different populations."( Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis.
Canonico, PL; Cargnin, S; Genazzani, AA; Terrazzino, S, 2018
)
0.48
" Low AZA dosing was defined as 6-thioguanine levels <125 pmol/8 × 10 erythrocytes and 6-methylmercaptopurine levels <5700 pmol/8 × 10 erythrocytes."( Prediction of Thiopurine Metabolite Levels Based on Haematological and Biochemical Parameters.
Bronsky, J; Hradsky, O; Karaskova, E; Lerchova, T; Mihal, V; Potuznikova, K; Siroka, J; Spenerova, M; Urbanek, L; Velganova-Veghova, M, 2019
)
0.51
"To describe the metabolic pathways and key factors implicated in the efficacy and toxicity of the thiopurine drugs and to indicate the opportunities to improve outcomes by monitoring and manipulating metabolic pathways, individualising dosage and strengthening the response."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
" Universal pre-treatment assessment of thiopurine methyltransferase activity and individualisation of dosage to manipulate metabolite thresholds could improve outcomes."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
"The efficacy and safety of thiopurines in autoimmune hepatitis can be improved by investigational efforts that establish monitoring strategies that allow individualisation of dosage and prediction of outcome, increase bioavailability of the active metabolites and demonstrate superiority to alternative agents."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
"To allow for tailored dosing and overcome swallowing difficulties, compounded liquid medication is often required in pediatric patients."( Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4.
Anagnostou, K; Cunha, CN; da Silva, SL; Dijkers, E; Ferreira, AO; Polonini, H,
)
0.13
"After giving 8 healthy beagle dogs 50 mg 6-MP in different dosage forms, plasma samples collected at different time points were analyzed for pharmacokinetic evaluation."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.56
"Two dosage forms showed the same pharmacokinetic characteristics."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.56
" The median daily dosage of TG was 20 mg/d (range 10-40 mg/d), and the median duration of TG use was 21."( Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.
Anderson, S; Ansari, AR; Bayoumy, AB; Boekema, PJ; Derijks, LJJ; Loganayagam, A; Mulder, CJJ; Sanderson, JD, 2021
)
0.62
"A retrospective evaluation of IBD patients intolerant to conventional thiopurines started on thioguanine from 2017 to 2019 with dosing guided by TDM was conducted."( Low-dose thioguanine guided by therapeutic drug monitoring is a safe and effective alternative in inflammatory bowel disease patients intolerant to conventional thiopurines.
Doecke, JD; Eqbal, A; Martin, A; Patrick, D, 2023
)
0.91
" Participants with optimal dosing in the morning had an earlier chronotype by corrected midpoint of sleep."( Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial.
Biglin, M; Bishehsari, F; Chouhan, V; Francey, L; Hogenesch, J; Jochum, S; Keshavarzian, A; Raff, H; Shaikh, M; Swanson, GR, 2023
)
0.91
"In the first study on a potential role of chronotherapy in IBD, we found (i) morning dosing of AZA or 6-MP resulted in more optimal metabolite profiles and (ii) host chronotype could help identify one-third of patients who would benefit from evening dosing."( Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial.
Biglin, M; Bishehsari, F; Chouhan, V; Francey, L; Hogenesch, J; Jochum, S; Keshavarzian, A; Raff, H; Shaikh, M; Swanson, GR, 2023
)
0.91
" Subgroup analyses were done for the dosage of thioguanine and the type of studies (prospective or retrospective)."( Effectiveness and safety of thioguanine as a maintenance therapy of inflammatory bowel disease: Systematic review, meta-analysis and meta-regression.
Dutta, U; Jena, A; Mangipudi, UK; Neelam, PB; Sebastian, S; Sharma, V; Telaprolu, H, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-aminopurinesAny aminopurine having the amino substituent at the 2-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Thioguanine Action Pathway4781
Thioguanine Metabolism Pathway14

Protein Targets (72)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.01120.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency3.15480.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency5.62340.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency63.81840.007215.758889.3584AID1224835; AID624030
acetylcholinesteraseHomo sapiens (human)Potency21.87940.002541.796015,848.9004AID1347395
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency53.54583.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.30790.006038.004119,952.5996AID1159521; AID1159523
GLS proteinHomo sapiens (human)Potency39.81070.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency2.04080.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.71430.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency15.33180.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
Smad3Homo sapiens (human)Potency1.41250.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency25.11890.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency66.84950.000657.913322,387.1992AID1259377
hypothetical protein, conservedTrypanosoma bruceiPotency14.12540.223911.245135.4813AID624173
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.82280.001022.650876.6163AID1224838; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency50.11870.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency5.49500.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency1.33810.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency27.08720.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency10.50250.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency2.85860.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.86820.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency17.90030.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency59.57970.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.11910.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency15.48710.01238.964839.8107AID1645842
67.9K proteinVaccinia virusPotency5.83460.00018.4406100.0000AID720579; AID720580
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency7.59360.001019.414170.9645AID743094; AID743191
IDH1Homo sapiens (human)Potency2.31090.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.23870.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency35.40860.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.38020.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency0.11610.143427.612159.8106AID1159516; AID1159519
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency60.07940.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.19100.039147.5451146.8240AID1224845
hemoglobin subunit betaHomo sapiens (human)Potency12.58560.31629.086131.6228AID1405; AID910; AID930
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency3.98110.316212.443531.6228AID902; AID924
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency2.05960.00419.984825.9290AID504444
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency39.81070.794321.275750.1187AID624246
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency4.61870.000627.21521,122.0200AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.15850.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.15850.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.15850.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency1.29950.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency7.07950.125912.234435.4813AID1458
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency31.50870.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency15.48710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency3.06720.002319.595674.0614AID651631; AID720552
Integrin beta-3Homo sapiens (human)Potency3.98110.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency3.98110.316211.415731.6228AID924
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency31.50870.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency10.00000.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency26.62960.060110.745337.9330AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)21.68700.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki12.25800.00000.930610.0000AID625196
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)18.40000.00022.45859.9600AID1884025; AID1884026; AID1884027; AID1884028
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)16.15900.11003.26419.0330AID625146
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)21.68700.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki12.25800.00010.949010.0000AID625196
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)0.60100.00021.557410.0000AID625243
Mitogen-activated protein kinase 3 Homo sapiens (human)IC50 (µMol)5.51600.00253.09269.5820AID625180
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)21.68700.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki12.25800.00000.965010.0000AID625196
Xanthine dehydrogenase/oxidaseHomo sapiens (human)IC50 (µMol)92.42000.00132.81389.8200AID287937
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12Kd18.00007.50007.50007.5000AID1129829
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PAX8Homo sapiens (human)AC500.56670.04885.435469.1700AID687027; AID687029; AID687032
Hypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)Km3.80001.15002.75635.9000AID274549; AID274562
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (477)

Processvia Protein(s)Taxonomy
T cell mediated cytotoxicityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
response to amphetamineHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine nucleotide biosynthetic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine ribonucleoside salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
locomotory behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
striatum developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cerebral cortex neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
central nervous system neuron developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
positive regulation of dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP catabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
adenine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
lymphocyte proliferationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dendrite morphogenesisHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein homotetramerizationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopaminergic neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
protein polyubiquitinationApoptosis regulator Bcl-2Homo sapiens (human)
apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
response to cytokineApoptosis regulator Bcl-2Homo sapiens (human)
B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of calcium ion transportApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
ossificationApoptosis regulator Bcl-2Homo sapiens (human)
ovarian follicle developmentApoptosis regulator Bcl-2Homo sapiens (human)
metanephros developmentApoptosis regulator Bcl-2Homo sapiens (human)
branching involved in ureteric bud morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
behavioral fear responseApoptosis regulator Bcl-2Homo sapiens (human)
B cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
release of cytochrome c from mitochondriaApoptosis regulator Bcl-2Homo sapiens (human)
regulation of cell-matrix adhesionApoptosis regulator Bcl-2Homo sapiens (human)
lymphoid progenitor cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
B cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
response to ischemiaApoptosis regulator Bcl-2Homo sapiens (human)
renal system processApoptosis regulator Bcl-2Homo sapiens (human)
melanin metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of nitrogen utilizationApoptosis regulator Bcl-2Homo sapiens (human)
autophagyApoptosis regulator Bcl-2Homo sapiens (human)
humoral immune responseApoptosis regulator Bcl-2Homo sapiens (human)
DNA damage responseApoptosis regulator Bcl-2Homo sapiens (human)
actin filament organizationApoptosis regulator Bcl-2Homo sapiens (human)
axonogenesisApoptosis regulator Bcl-2Homo sapiens (human)
female pregnancyApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell population proliferationApoptosis regulator Bcl-2Homo sapiens (human)
male gonad developmentApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressApoptosis regulator Bcl-2Homo sapiens (human)
response to radiationApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
post-embryonic developmentApoptosis regulator Bcl-2Homo sapiens (human)
response to iron ionApoptosis regulator Bcl-2Homo sapiens (human)
response to UV-BApoptosis regulator Bcl-2Homo sapiens (human)
response to gamma radiationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of gene expressionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of autophagyApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
regulation of glycoprotein biosynthetic processApoptosis regulator Bcl-2Homo sapiens (human)
mesenchymal cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
cochlear nucleus developmentApoptosis regulator Bcl-2Homo sapiens (human)
gland morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
regulation of transmembrane transporter activityApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of ossificationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
hair follicle morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
axon regenerationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein stabilityApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
glomerulus developmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cellular pH reductionApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein localizationApoptosis regulator Bcl-2Homo sapiens (human)
myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
T cell differentiation in thymusApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationApoptosis regulator Bcl-2Homo sapiens (human)
osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
response to nicotineApoptosis regulator Bcl-2Homo sapiens (human)
organ growthApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of multicellular organism growthApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to glucose starvationApoptosis regulator Bcl-2Homo sapiens (human)
response to hydrogen peroxideApoptosis regulator Bcl-2Homo sapiens (human)
neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
T cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
CD8-positive, alpha-beta T cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
ear developmentApoptosis regulator Bcl-2Homo sapiens (human)
regulation of viral genome replicationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane permeabilityApoptosis regulator Bcl-2Homo sapiens (human)
focal adhesion assemblyApoptosis regulator Bcl-2Homo sapiens (human)
spleen developmentApoptosis regulator Bcl-2Homo sapiens (human)
thymus developmentApoptosis regulator Bcl-2Homo sapiens (human)
digestive tract morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
oocyte developmentApoptosis regulator Bcl-2Homo sapiens (human)
skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
pigment granule organizationApoptosis regulator Bcl-2Homo sapiens (human)
stem cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
homeostasis of number of cells within a tissueApoptosis regulator Bcl-2Homo sapiens (human)
B cell receptor signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
response to glucocorticoidApoptosis regulator Bcl-2Homo sapiens (human)
neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
defense response to virusApoptosis regulator Bcl-2Homo sapiens (human)
establishment of localization in cellApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane potentialApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of mitochondrial depolarizationApoptosis regulator Bcl-2Homo sapiens (human)
hematopoietic stem cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to organic substanceApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to hypoxiaApoptosis regulator Bcl-2Homo sapiens (human)
reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cell-cell adhesionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorApoptosis regulator Bcl-2Homo sapiens (human)
epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of anoikisApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
folic acid-containing compound biosynthetic process2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
tetrahydrofolate biosynthetic process2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
folic acid biosynthetic process2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 3 Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-templated transcriptionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 3 Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 3 Homo sapiens (human)
phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
sensory perception of painMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 3 Homo sapiens (human)
BMP signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 3 Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 3 Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 3 Homo sapiens (human)
peptidyl-tyrosine autophosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
myelinationMitogen-activated protein kinase 3 Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 3 Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 3 Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 3 Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 3 Homo sapiens (human)
cartilage developmentMitogen-activated protein kinase 3 Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 3 Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 3 Homo sapiens (human)
face developmentMitogen-activated protein kinase 3 Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
trachea formationMitogen-activated protein kinase 3 Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 3 Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 3 Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 3 Homo sapiens (human)
xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
negative regulation of TORC1 signalingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 3 Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 3 Homo sapiens (human)
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
response to cytokineBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsBcl-2-like protein 1Homo sapiens (human)
ovarian follicle developmentBcl-2-like protein 1Homo sapiens (human)
in utero embryonic developmentBcl-2-like protein 1Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
endocytosisBcl-2-like protein 1Homo sapiens (human)
germ cell developmentBcl-2-like protein 1Homo sapiens (human)
spermatogenesisBcl-2-like protein 1Homo sapiens (human)
male gonad developmentBcl-2-like protein 1Homo sapiens (human)
apoptotic mitochondrial changesBcl-2-like protein 1Homo sapiens (human)
fertilizationBcl-2-like protein 1Homo sapiens (human)
regulation of cytokinesisBcl-2-like protein 1Homo sapiens (human)
positive regulation of mononuclear cell proliferationBcl-2-like protein 1Homo sapiens (human)
ectopic germ cell programmed cell deathBcl-2-like protein 1Homo sapiens (human)
regulation of growthBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
dendritic cell proliferationBcl-2-like protein 1Homo sapiens (human)
response to cycloheximideBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl-2-like protein 1Homo sapiens (human)
epithelial cell proliferationBcl-2-like protein 1Homo sapiens (human)
negative regulation of developmental processBcl-2-like protein 1Homo sapiens (human)
neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
defense response to virusBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane potentialBcl-2-like protein 1Homo sapiens (human)
cellular response to amino acid stimulusBcl-2-like protein 1Homo sapiens (human)
cellular response to alkaloidBcl-2-like protein 1Homo sapiens (human)
cellular response to gamma radiationBcl-2-like protein 1Homo sapiens (human)
apoptotic process in bone marrow cellBcl-2-like protein 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
hepatocyte apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of execution phase of apoptosisBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
negative regulation of protein localization to plasma membraneBcl-2-like protein 1Homo sapiens (human)
negative regulation of reproductive processBcl-2-like protein 1Homo sapiens (human)
negative regulation of dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (110)

Processvia Protein(s)Taxonomy
nucleotide bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
magnesium ion bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protease bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
channel activityApoptosis regulator Bcl-2Homo sapiens (human)
channel inhibitor activityApoptosis regulator Bcl-2Homo sapiens (human)
ubiquitin protein ligase bindingApoptosis regulator Bcl-2Homo sapiens (human)
identical protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
sequence-specific DNA bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein heterodimerization activityApoptosis regulator Bcl-2Homo sapiens (human)
BH3 domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein phosphatase 2A bindingApoptosis regulator Bcl-2Homo sapiens (human)
molecular adaptor activityApoptosis regulator Bcl-2Homo sapiens (human)
DNA-binding transcription factor bindingApoptosis regulator Bcl-2Homo sapiens (human)
BH domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
magnesium ion binding2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase activity2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
ATP binding2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
kinase activity2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
phosphotyrosine residue bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 3 Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 3 Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase 3 Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingBcl-2-like protein 1Homo sapiens (human)
protein kinase bindingBcl-2-like protein 1Homo sapiens (human)
identical protein bindingBcl-2-like protein 1Homo sapiens (human)
BH3 domain bindingBcl-2-like protein 1Homo sapiens (human)
BH domain bindingBcl-2-like protein 1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (85)

Processvia Protein(s)Taxonomy
cytoplasmHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum membraneApoptosis regulator Bcl-2Homo sapiens (human)
nucleusApoptosis regulator Bcl-2Homo sapiens (human)
cytoplasmApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrionApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulumApoptosis regulator Bcl-2Homo sapiens (human)
cytosolApoptosis regulator Bcl-2Homo sapiens (human)
membraneApoptosis regulator Bcl-2Homo sapiens (human)
nuclear membraneApoptosis regulator Bcl-2Homo sapiens (human)
myelin sheathApoptosis regulator Bcl-2Homo sapiens (human)
BAD-BCL-2 complexApoptosis regulator Bcl-2Homo sapiens (human)
protein-containing complexApoptosis regulator Bcl-2Homo sapiens (human)
pore complexApoptosis regulator Bcl-2Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
nuclear envelopeMitogen-activated protein kinase 3 Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 3 Homo sapiens (human)
early endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
late endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 3 Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 3 Homo sapiens (human)
cytosolMitogen-activated protein kinase 3 Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 3 Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 3 Homo sapiens (human)
caveolaMitogen-activated protein kinase 3 Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 3 Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 3 Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 3 Homo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytoplasmBcl-2-like protein 1Homo sapiens (human)
mitochondrionBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial inner membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial matrixBcl-2-like protein 1Homo sapiens (human)
endoplasmic reticulumBcl-2-like protein 1Homo sapiens (human)
centrosomeBcl-2-like protein 1Homo sapiens (human)
cytosolBcl-2-like protein 1Homo sapiens (human)
synaptic vesicle membraneBcl-2-like protein 1Homo sapiens (human)
nuclear membraneBcl-2-like protein 1Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (363)

Assay IDTitleYearJournalArticle
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID289853Growth inhibition of human MDA-MB-435 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289814Growth inhibition of human COLO205 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289831Growth inhibition of human SK-MEL-5 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289848Growth inhibition of human DU145 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113930Anticancer activity against Homo sapiens (human) ACHN cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID289817Growth inhibition of human HCT15 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289801Growth inhibition of human CCRF-CEM cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID361326Inhibition of beta-hexosaminidase A at pH 4.3 assessed as residual enzyme activity2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1113948Anticancer activity against Homo sapiens (human) SNB75 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289809Growth inhibition of human NCI-H226 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID98788Median survival time at a compound dose of 25 mg/Kg, in mice bearing L1210 cells on days 1 and 51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID98786Median survival time at a compound dose of 200 mg/kg, in mice bearing L1210 cells on days 1 and 5; Toxic1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID289806Growth inhibition of human EKVX cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113965Anticancer activity against Homo sapiens (human) NCI-H23 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1918597Antiproliferative activity against human THP-1 cells with low HGPRT expression incubated for 48 hrs by CellTiter-Glo2 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID274562Inhibition of human HGPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID289821Growth inhibition of human SF268 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1113950Anticancer activity against Homo sapiens (human) SNB19 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID355579Antiproliferative activity against human HT-29 cells at 10 ug after 48 hrs by two-layer agar-diffusion method
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1113927Anticancer activity against Homo sapiens (human) TK10 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID287937Inhibition of human xanthine oxidase2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors.
AID67773Compound was evaluated for its effect on survival of aerobic EMT6 tumor cells when exposed to concentration at 10e-7 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID289820Growth inhibition of human SW620 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID431396Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID289854Growth inhibition of human BT549 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID289810Growth inhibition of human NCI-H23 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113926Anticancer activity against Homo sapiens (human) SN12C cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1326906Cytotoxicity against human RFX393 cells measured after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 1223-Hydrazinoindolin-2-one derivatives: Chemical classification and investigation of their targets as anticancer agents.
AID289803Growth inhibition of human MOLT4 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289830Growth inhibition of human SK-MEL-28 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113956Anticancer activity against Homo sapiens (human) HT-29 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID316226Inhibition of PAK1 at 31 uM2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID510577Inhibition of RNA synthesis in human CEM cells assessed as BrU incorporation using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID67776Compound was evaluated for its effect on survival of hypoxic EMT6 tumor cells when exposed to concentration at 10e-5 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID1113952Anticancer activity against Homo sapiens (human) SF295 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID274549Inhibition of human HGPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID289808Growth inhibition of human HOP92 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289816Growth inhibition of human HCT116 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289823Growth inhibition of human SF539 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289811Growth inhibition of human NCI-H322M cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1113942Anticancer activity against Homo sapiens (human) SK-MEL-28 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289845Growth inhibition of human TK10 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID289815Growth inhibition of human HCC2998 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113932Anticancer activity against Homo sapiens (human) NCI/ADR-RES cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289818Growth inhibition of human HT29 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1884026Inhibition of TAP-tagged SARS-CoV-2 papain-like protease nsp232022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1113938Anticancer activity against Homo sapiens (human) IGROV1 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289841Growth inhibition of human ACHN cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1326910Cytotoxicity against human UO31 cells measured after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 1223-Hydrazinoindolin-2-one derivatives: Chemical classification and investigation of their targets as anticancer agents.
AID289805Growth inhibition of human A549 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1884025Inhibition of TAP-tagged SARS-CoV-2 papain-like protease nsp1232022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1113925Anticancer activity against Homo sapiens (human) UO31 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289832Growth inhibition of human UACC257 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289835Growth inhibition of human OVCAR-3 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113922Anticancer activity against Homo sapiens (human) DU145 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1918598Antiproliferative activity against human SK-BR-3 cells with low HGPRT expression incubated for 48 hrs by CellTiter-Glo2 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID1113959Anticancer activity against Homo sapiens (human) HCT116 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID510575Cell cycle arrest in human CEM cells assessed as accumulation at G2/M phase using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1113934Anticancer activity against Homo sapiens (human) OVCAR8 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113931Anticancer activity against Homo sapiens (human) 786-0 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289847Growth inhibition of human PC3 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1918595Antiproliferative activity against HEK293T cells with high HGPRT expression incubated for 48 hrs by CellTiter-Glo2 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID1113964Anticancer activity against Homo sapiens (human) HOP92 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289824Growth inhibition of human SNB19 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289852Growth inhibition of human HS578T cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289837Growth inhibition of human OVCAR8 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID67778Compound was evaluated for its effect on survival of hypoxic EMT6 tumor cells when exposed to concentration at 10e-7 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1113951Anticancer activity against Homo sapiens (human) SF539 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID289840Growth inhibition of human A498 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID274548Antiplasmodial activity against Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1113955Anticancer activity against Homo sapiens (human) SW620 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID274712Growth inhibition of Jurkat cell2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
AID510579Inhibition of DNA synthesis in human CEM cells assessed as BrDU incorporation using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID355584Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID431399Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID289829Growth inhibition of human SK-MEL-2 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289844Growth inhibition of human SN12C cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID274563Inhibition of Plasmodium falciparum HGXPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID289826Growth inhibition human U251 of cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID289807Growth inhibition of human HOP62 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113949Anticancer activity against Homo sapiens (human) U251 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289833Growth inhibition of human UACC62 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID289836Growth inhibition of human OVCAR4 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID289855Growth inhibition of human T47D cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289802Growth inhibition of human K562 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1113916Anticancer activity against Homo sapiens (human) T47D cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID510563Cytotoxicity against human A549 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID355580Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1216055Cytotoxicity against human Patu-T cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1113918Anticancer activity against Homo sapiens (human) BT549 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID184629Compound was tested for lethal dose at day 16 against rat1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nucleosides of azathioprine and thiamiprine as antiarthritics.
AID289822Growth inhibition of human SF295 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1216059Cytotoxicity against human Patu-02 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID289842Growth inhibition of human CAKI1 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID510566Cytotoxicity against human K562 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1113973Anticancer activity against Homo sapiens (human) CCRF-CEM cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID137888Ratio of the median survival time (treated(T) versus control(C)) at a dose of 25 mg/Kg on days 1 and 51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1113933Anticancer activity against Homo sapiens (human) SKOV3 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113937Anticancer activity against Homo sapiens (human) OVCAR3 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1884030Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID355585Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID1113963Anticancer activity against Homo sapiens (human) NCI-322M cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1216057Cytotoxicity against human Aspc-1 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1113940Anticancer activity against Homo sapiens (human) SK-MEL-5 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113966Anticancer activity against Homo sapiens (human) HOP62 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289825Growth inhibition of human SNB75 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1113969Anticancer activity against Homo sapiens (human) SR cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1918599Antiproliferative activity against human K562 cells with low HGPRT expression assessed as cell survival at 1000 uM and incubated for 48 hrs by CellTiter-Glo2 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID1113954Anticancer activity against Homo sapiens (human) KM12 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1216058Cytotoxicity against human PANC1 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1113944Anticancer activity against Homo sapiens (human) MDA-MB-435 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113968Anticancer activity against Homo sapiens (human) EKVX cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289834Growth inhibition of human IGROV1 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID289838Growth inhibition of human SK-OV-3 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1718097Inhibition of SARS-CoV C-terminal 6His-tagged papain-like protease expressed in Escherichia coli BL21(DE3) using ubiquitin-AMC as substrate preincubated for 10 mins followed by substrate addition by luminescence spectrometric method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1918601Downregulation of HGPRT mRNA expression in human K562 cells at 1 mM measured after 48 hrs by qPCR analysis2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID289828Growth inhibition of human M14 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID274714Growth inhibition of Jurkat cell overexpressing BclXL2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
AID289819Growth inhibition of human KM12 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID230176The number of mice survived to that of total at a dose of 25 mg/Kg on 30th day: 4/51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1129827Inhibition of GST-tagged Escherichia coli HPPK expressed in Escherichia coli using 6-hydroxymethyl-7,8-dihydropterin hydrochloride as substrate at 250 uM after 20 mins by luminescence assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
The identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase.
AID1918596Antiproliferative activity against human K562 cells with low HGPRT expression incubated for 48 hrs by CellTiter-Glo2 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID289827Growth inhibition of human LOX IMVI cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID178124Antiarthritic activity in rat determined by adjuvant arthritis assay in rat1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nucleosides of azathioprine and thiamiprine as antiarthritics.
AID510581Induction of mitotic arrest in human CEM cells assessed as pH3Ser10 positive cells at 5 times IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID510574Cell cycle arrest in human CEM cells assessed as accumulation at G2/M phase using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1113962Anticancer activity against Homo sapiens (human) NCI-H522 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID96817In vitro inhibitory concentration required for 50% inhibition of L1210 cell growth;(ID 50*1E-12)1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510578Inhibition of DNA synthesis in human CEM cells assessed as BrDU incorporation using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID274558Inhibition of Plasmodium lophurae 6 oxopurine phosphoribosyl transferase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1767036Substrate activity at Helicobacter pylori XGHPRT assessed as Kcat using purine base and PRib-PP as substrate measured for 60 sec by spectrophotometric method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID181153Compound was tested for dose at which there was no significant weight loss in rat at day 161989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nucleosides of azathioprine and thiamiprine as antiarthritics.
AID289849Growth inhibition of human MCF7 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID510576Inhibition of RNA synthesis in human CEM cells assessed as BrU incorporation using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1767040Antibacterial activity against Helicobacter pylori assessed growth inhibition at 50 uM incubated for 3 days2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID1113941Anticancer activity against Homo sapiens (human) UACC257 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID137887Ratio of the median survival time (treated(T) versus control(C)) at a dose of 100 mg/kg, on days 1 and 51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID431398Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1216056Cytotoxicity against human Patu-S cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID98779Median survival time at a compound dose of 100 mg/kg, in mice bearing L1210 cells on days 1 and 51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID274547Inhibition of [3H]hypoxanthine uptake in Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID681884TP_TRANSPORTER: inhibition of bimane-GS efflux in the presence of 6-thioguanine at a concentration of 100uM in MRP4-expressing HepG2 cells2004The international journal of biochemistry & cell biology, Feb, Volume: 36, Issue:2
Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione.
AID431395Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID510567Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID289804Growth inhibition of human RPMI8226 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID289851Growth inhibition of MDA-MB-231 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID1113929Anticancer activity against Homo sapiens (human) A498 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID289812Growth inhibition of human NCI-H460 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID510569Induction of apoptosis in human CEM cells using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1113972Anticancer activity against Homo sapiens (human) K562 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1216053Cytotoxicity against human T3M4 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID289813Growth inhibition of human NCI-H522 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID510564Cytotoxicity against human CEM cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1884027Inhibition of SARS-CoV-2 papain-like protease-mediated de-ISGylation2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID274713Growth inhibition of Jurkat cell overexpressing Bcl22006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
AID289856Growth inhibition of human OVCAR5 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID510565Cytotoxicity against human CEM-DNR-B cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID510580Induction of mitotic arrest in human CEM cells assessed as pH3Ser10 positive cells at IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID355578Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID274564Inhibition of Escherichia coli Sphi609 cells expressing Plasmodium falciparum HGXPRT2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID510568Induction of apoptosis in human CEM cells using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1113960Anticancer activity against Homo sapiens (human) COLO205 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113939Anticancer activity against Homo sapiens (human) UACC62 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1129829Binding affinity to GST-tagged Escherichia coli HPPK expressed in Escherichia coli by SPR assay based alternative equilibrium affinity method in presence of AMP-CPP2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
The identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase.
AID289846Growth inhibition of human UO31 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1918602Downregulation of HGPRT mRNA expression in human SK-BR-3 cells at 1 mM measured after 48 hrs by qPCR analysis2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID510572Cell cycle arrest in human CEM cells assessed as accumulation at S phase using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID98799Median survival time when no dose was administered in mice bearing L1210 cells on days 1 and 51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID93940Cytotoxicity was determined in vitro in murine leukemia L1210 Cells1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adducts.
AID230168The number of mice survived to that of total at a dose of 100 mg/kg on 30th day1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID274715Ratio of GI50 for Jurkat cells overexpressing Bcl2 or BclXL to normal Jurkat cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
AID1113946Anticancer activity against Homo sapiens (human) MALME-3M cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID355583Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID289839Growth inhibition of human 786O cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID1884028Inhibition of SARS-CoV-2 papain-like protease2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID67770Compound was evaluated for its effect on survival of aerobic EMT6 tumor cells when exposed to concentration at 10E-5 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID510571Cell cycle arrest in human CEM cells assessed as accumulation at G0/G1 phase using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1113961Anticancer activity against Homo sapiens (human) NCI-H460 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID274565Inhibition of Escherichia coli Sphi609 cells expressing human HGPRT2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID510570Cell cycle arrest in human CEM cells assessed as accumulation at G0/G1 phase using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1113935Anticancer activity against Homo sapiens (human) OVCAR5 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1113957Anticancer activity against Homo sapiens (human) HCT15 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID97793Effect dose of 50 mg/kg on day 3, before L1210 cell transplantation in mice1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID1113945Anticancer activity against Homo sapiens (human) M14 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113943Anticancer activity against Homo sapiens (human) SK-MEL-2 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1894171Inhibition of SARS-CoV Papain-like protease2021European journal of medicinal chemistry, Mar-15, Volume: 214FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1216054Cytotoxicity against human Colo-357 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1767037Substrate activity at hexa-his tagged Helicobacter pylori XGHPRT assessed as apparent Km using purine base and PRib-PP as substrate measured for 60 sec by spectrophotometric method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID67772Compound was evaluated for its effect on survival of aerobic EMT6 tumor cells when exposed to concentration at 10e-6 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID274550Inhibition of Plasmodium falciparum HGXPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1113936Anticancer activity against Homo sapiens (human) OVCAR4 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID584551Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining measured after 6 hrs infection2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID98793Median survival time at a compound dose of 50 mg/kg, in mice bearing L1210 cells on days 1 and 51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID355586Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1326917Cytotoxicity against human U251 cells measured after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 1223-Hydrazinoindolin-2-one derivatives: Chemical classification and investigation of their targets as anticancer agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID289843Growth inhibition of human RXF393 cells after 48 hrs by SRB protein assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
AID355582Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID233530The number of mice survived to that of total when no compound dose was given on 30th day1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID1113967Anticancer activity against Homo sapiens (human) A549/ATCC cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID137889Ratio of the median survival time (treated(T) versus control(C)) at a dose of 50 mg/kg, on days 1 and 51981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1113971Anticancer activity against Homo sapiens (human) RPMI8266 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113953Anticancer activity against Homo sapiens (human) SF268 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID355581Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1884029Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as viral growth inhibition2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID510573Cell cycle arrest in human CEM cells assessed as accumulation at S phase using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID67775Compound was evaluated for its effect on survival of hypoxic EMT6 tumor cells when exposed to concentration at 10E-4 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID67777Compound was evaluated for its effect on survival of hypoxic EMT6 tumor cells when exposed to concentration at 10E-6 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID1113919Anticancer activity against Homo sapiens (human) Hs 578T cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID274557Inhibition of Plasmodium chabaudi 6 oxopurine phosphoribosyl transferase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID230180The number of mice survived to that of total at a dose of 50 mg/Kg on 30th day1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice.
AID1918600Drug resistance of human SK-BR-3 cells assessed as percentage of resistant cells at 1 mM2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells.
AID1113921Anticancer activity against Homo sapiens (human) MCF7 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1113924Anticancer activity against Homo sapiens (human) PC3 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1113923Anticancer activity against Homo sapiens (human) RXF393 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID67769Compound was evaluated for its effect on survival of aerobic EMT6 tumor cells when exposed to concentration at 10E-4 M1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
AID1113928Anticancer activity against Homo sapiens (human) CAKI-1 cells by SRB assay2013Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, May, Volume: 22, Issue:5
Synthesis and anticancer evaluation of novel 3,5-diaryl-thiazolo[4,5-
AID1894172Inhibition of MERS coronavirus full-length USP2 catalytic domain (258 to 605 residues) expressed in Escherichia coli Rosetta (DE3) using ubiquitin-7-amino-4-trifluoromethylcoumarin as substrate by luminescence based spectrometer analysis2021European journal of medicinal chemistry, Mar-15, Volume: 214FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1216060Cytotoxicity against human DAN-G cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346059Human inosine monophosphate dehydrogenase 2 (Nucleoside synthesis and metabolism)2008Scandinavian journal of clinical and laboratory investigation, , Volume: 68, Issue:4
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.
AID1346059Human inosine monophosphate dehydrogenase 2 (Nucleoside synthesis and metabolism)2003Current pharmaceutical design, , Volume: 9, Issue:31
Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites.
AID1346128Human inosine monophosphate dehydrogenase 1 (Nucleoside synthesis and metabolism)2003Current pharmaceutical design, , Volume: 9, Issue:31
Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites.
AID1346128Human inosine monophosphate dehydrogenase 1 (Nucleoside synthesis and metabolism)2008Scandinavian journal of clinical and laboratory investigation, , Volume: 68, Issue:4
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,575)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901265 (49.13)18.7374
1990's499 (19.38)18.2507
2000's372 (14.45)29.6817
2010's339 (13.17)24.3611
2020's100 (3.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 6.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index6.38 (24.57)
Research Supply Index8.01 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (6.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials295 (10.90%)5.53%
Reviews138 (5.10%)6.00%
Case Studies177 (6.54%)4.05%
Observational4 (0.15%)0.25%
Other2,092 (77.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]